Open AccessEffect of different dipeptidyl peptidase-4 inhibitors on lipid profile of type II diabetic patients
Author(s) -
T. Z. Omran,
Ghufran Ismaeel
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns2.5229
Subject(s) - vildagliptin , sitagliptin , linagliptin , metformin , medicine , lipid profile , sitagliptin phosphate , dipeptidyl peptidase 4 , type 2 diabetes , analysis of variance , diabetes mellitus , cholesterol , gastroenterology , endocrinology , triglyceride , pharmacology
Objective: In this research study, we aimed to study the effect of dipeptidyl peptidase-4 inhibitors (Gliptins drug) on the lipid profile of diabetic type 2 patients. Materials/methods: Type 2 diabetic (200) patients taking Gliptin ± metformin and willing to participate in the study were included. Lipid profile tests (total cholesterol, HDL, non-HDL, LDL, VLDL, triglycerides level) of the patients were done in a pathological laboratory on routine health checkups. The mean and S.E.M of each parameter were calculated. All data were subjected to a Student's t-test. Comparison between the treatments was done by using one-way ANOVA- Bonferroni multiple comparison tests. Results: All 200 patients have completed the questionnaire and monitored twice for six months (initial visit and final visit). Of the total participants, 109 (54.50%) were males and 91 (45.50%) were females. Ninety tow (46%) were taking vildagliptin + metformin while 73 (36.5%) patients were taking vildagliptin, 20 (10%) were taking sitagliptin + metformin, 15 (7.5%) were taking linagliptin and only 1 (0.5%) patients were taking sitagliptin. Conclusions: The present findings showed that vildagliptin can reduce the total cholesterol level, Non-HDL level, and triglycerides significantly. Linagliptin can reduce the total cholesterol Level and non-HDL significantly.